Menopause Advocacy and Policy Reform Guide

In a conference room at the Department of Health and Human Services, lawyers, physicians, and advocates spent four hours talking about the one hormone treatment nearly everyone in the room already agreed was safe, cheap, and badly underused: vaginal estrogen. Then the conversation hit a wall that had nothing to do with medicine. Social media platforms will not reliably let small creators say the word vagina. The fix floated in the room was half a joke: rename it sepsis prevention cream, so the algorithm lets it through (13:19).

That anecdote, told by Dr. Kelly Casperson on her podcast You Are Not Broken, says something about where women's health policy stands right now. The science is often settled. The politics are often friendlier than expected. The obstacle sits somewhere else entirely, in a content moderation rule, an insurance form, or a law that was never written. Weiss-Wolf runs a women's leadership center at NYU School of Law. She spent about 11 years building policy around menstruation before menopause caught her attention around 2020 (02:44). She is also the author of a new book, When in Menopause: A User's Manual and Citizen's Guide, and she had just testified at a Senate hearing on aging, one of four witnesses alongside three physicians.

Weiss-Wolf's organizing idea is that advocacy has no single template. She describes it as a choose-your-own-adventure story, the kind of book where every reader takes a different path to the same ending.

"I describe advocacy itself as, um, a, a choose your own adventure book... It's not one roadmap. It's not one set of skills." — Jennifer Weiss-Wolf [07:27]

That framing came out of her menstruation work, where she found herself next to athletes, artists, and teenagers who cared nothing for legislative language but cared deeply about the same outcome. Menopause, she admits, has turned out to be a harder problem. Not because people care less, but because the underlying science has been neglected at the macro level for decades, starved of federal research funding even while individual doctors kept accumulating real evidence on the ground (10:22).

A Pattern That Keeps Repeating

Weiss-Wolf went looking for precedent in old newspapers and found two earlier moments when menopause briefly became a national conversation, and then wasn't. The first was the 1960s and 1970s, when estrogen was popularized partly for women's health and partly, as physician Robert Wilson argued in his book Feminine Forever, for men's benefit. Safety concerns followed quickly. A campaign led by consumer advocate Ralph Nader and allied feminists pushed the FDA to require added warnings, which is where today's hormone labeling rules originated (25:41).

The second moment came in 1992, when a record number of women were elected to Congress in what was called the Year of the Woman (26:33). Weiss-Wolf found an October 1992 New York Times op-ed titled Mighty Menopause that she says reads as if it were written yesterday. That political wave helped fund the Women's Health Initiative (WHI) in 1993, the largest single investment the government had made in women's health research up to that point (27:09). Then, in 2002, a WHI press announcement on hormone therapy risk landed at a moment when, Weiss-Wolf and Casperson both suggest, a single skeptical voice at an influential newspaper had already primed the audience for alarm (27:46, 30:48). Hormone use collapsed and stayed low for years. On the podcast, the two openly wondered aloud whether a decade of expanding female political power had been met, not entirely by coincidence, with a message that made women afraid of their own bodies and too sick to keep pushing (32:11).

What is different now, Weiss-Wolf argues, is that no single reporter or network can control the story the way one newspaper columnist could in 1990. Doctors, patients, and researchers can publish directly.

"The few and the mighty are crumbling to, to the power of, of people who are great communicators." — Dr. Kelly Casperson [29:44]

She calls this a form of insurance against a repeat of 2002: if a federal agency tries to land a controversial announcement without context again, there are now thousands of doctors and patients ready to push back in real time.

The Gaps Policy Hasn't Closed

Media visibility has not solved the legal problem underneath it. Weiss-Wolf is blunt that no US anti-discrimination law, not the Americans with Disabilities Act, not the Pregnancy Discrimination Act, not any state age-discrimination statute, explicitly covers menopause (36:59). That gap makes her cautious about the workplace benefits many employers are now floating.

"Without that protection, I would not feel comfortable telling any employee that they should march into their HR office and demand menopause benefits." — Jennifer Weiss-Wolf [38:04]

Her worry is concrete: an employee who announces she is using a menopause accommodation could be quietly demoted or passed over for a project, with no legal claim available if it happens. She wants lawyers to build a real anti-discrimination framework before advocates spend political capital on perks that offer no protection underneath them.

A second structural gap sits inside insurance. Casperson points out that Washington State recently passed its own menopause workplace law, yet prior authorization requirements for generic, FDA-approved hormone medications remain a major barrier to actually getting treatment (39:37, 40:05). A fan in a hot office, she notes, does nothing for a patient who cannot get her prescription approved. Both agree that state-level workplace gestures look good in a press release but do not touch the insurance layer where access actually breaks down. At the Senate hearing, three physicians and Weiss-Wolf testified, and every witness centered their testimony on hormone access, including data suggesting women between ages 50 and 60 on hormone therapy showed increased longevity, a framing Casperson says would have been unthinkable at a Senate hearing on aging a decade ago (44:15).

So what does an ordinary person, or a rushed clinician, actually do with all this? Weiss-Wolf's answer avoids grand gestures. Writing directly to a state or federal legislator, or filing a comment during an FDA public comment period, moves more than a social media post ever will. Casperson points to the open comment campaign that helped secure a dedicated FDA hearing day on female testosterone as proof it works (17:49). For clinicians seeing dozens of patients a day with no time to spare, her suggestion is smaller still: keep a resource book in the waiting room, or have staff post reliable links, since every patient who walks through the door is already a chance to spread accurate information without adding a single task to the schedule (48:18). And for everyone else, she points to spaces that already exist. Her own first event for the book is not a lecture hall but a mini class at her gym, taught in leggings and barre socks, because she believes advocacy does not survive without community.

"Advocacy doesn't exist without community." — Jennifer Weiss-Wolf [52:38]

Both women end on a generational note. Casperson frames it as two waves colliding: an overburdened healthcare system built around treating symptoms after they appear, meeting a cohort of younger patients who have grown up expecting prevention instead of suffering (34:29). Weiss-Wolf adds that Gen X women, long underestimated, pair naturally with millennials who were raised to expect more, a combination she thinks could reshape how the country treats aging bodies. None of it depends on a single leader or a tidy headline moment. It depends, by her own account, on a lot of separate people deciding that their particular skill, whether it is legislative drafting, a singing voice, or a Tuesday morning barre class, counts as advocacy too.